CryoLife Announces Launch of BioGlue Surgical Adhesive in the Japanese Market CryoLife, a specialist in the processing and delivery of implantable living human tissues for application in vascular and cardiac surgeries across Canada and the U.S., has introduced BioGlue surgical adhesive in the Japanese market. The product will be available in hospitals in May 2011.
In September 2010, the Japanese Ministry of Health, Labor and Welfare (MHLW) has provided Shonin approval for using BioGlue adhesive in the aortic dissection repair.
Century Medical (CMI), a partner of CryoLife, has been selected to market BioGlue adhesive in Japan. The material will be used by cardiac surgeons and help solve critical issues in cardiac surgeries.
Steven G. Anderson, CryoLife’s President and CEO, stated that the company is happy about the product launch in the Japanese market BioGlue adhesive is a safe and efficient product has been used in over 615,000 procedures across the globe.
The shipment of first BioGlue order is expected in April end or early May 2011. CryoLife anticipates that CMI will achieve nearly $600,000 sales during the first year. CryoLife and CMI presented an overview of BioGlue at the Japanese Society of Cardiovascular Surgery conference held in Tokyo in February 2011.
Source: http://www.cryolife.com/